Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results

- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively

- Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period